Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that James Keeling has been appointed as Chief Financial Officer (CFO).
James joins from JGK Financial Management, a company set up to support SMEs in their growth phase providing expertise in business & financial planning, funding, sustainable investments and exit strategies. This has included working with business based in Loughborough University Science, Enterprise Park and as Interim CFO for Stevenage Bioscience Catalyst.
Prior to founding JGK Financial Management, James worked Internationally in the Pharmaceutical and TMT sectors with GlaxoSmithKline, BT Group and COLT Technologies having been based in the UK and Asia, leading Commercial Finance, Financial Governance & Control and Finance Transformation initiatives.
James started his career at the Wellcome Foundation as a Research Scientist. He has a BSc (Hons) degree in Applied Biology, is a qualified Chartered Global Management Accountant and is a Fellow of the Chartered Institute of Management Accountants.
Dr Sally Ann Forsyth, CEO at SBC said “James brings a wealth of experience within the pharmaceutical, technology and SME community and will be a fantastic addition to the SBC team.”
James Keeling, incoming CFO said “I am delighted to be joining Sally Ann and the team at SBC to help support and shape the current and future planning and strategy. It is an exciting time of continued Innovation and Technological advancement in medicines and I look forward to supporting scientific excellence that the Biotech companies at SBC represent through their world class Research and Development.”
Agility Health Tech